Vertex Pharmaceuticals Misses Sales Estimates; UK May Discontinue Use of Its Costly Cystic Fibrosis Treatments

Q3 sales decline due to weak demand for older treatments; UK's NICE deems cost of Vertex's treatments too high, could deny future access to new CF patients.